The American pharmaceutical company Johnson & Johnson obtained a net profit of 17,941 million dollars in 2022 (about 19,200 million euros at the current exchange rate), which represents a reduction of 14.1% compared to the profits of a year earlier, due to lower sales of its vaccine against covid-19.
According to the information released by the company itself this Thursday, only in the fourth quarter the result was 3,520 million dollars, 25.7% less than in the same period of 2021, partly because sales in the last three months of 2022 they fell by 4.4%, to 23,706 million dollars.
Throughout the year, however, the turnover amounted to 94,943 million dollars, which represents an increase of 1.3% in the interannual rate.
By business segments, the pharmaceutical division, which is the most important, entered 52,563 million dollars, 1.7% more, while sales of medical devices obtained 27,427 million dollars, 1.4% more.
On the contrary, in the branch of consumer products for health, the annual turnover fell by 0.5%, up to 14,953 million dollars.